Current stock page

Catalysts

VKTX Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

VKTXViking Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

BearishEdge 7/10
$29.22+$1.64 (+5.95%)

Latest quote

  • Momentum
    47
  • Value
    —
  • Quality
    33
  • Risk resilience
    41
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 10, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 41/100

Momentum 47/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 16.86%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 47/100AIQ Edge 7/10 Above Peers
Beat rate
13%
1 of 8 reported periods
Average surprise
-26.1%
Across covered historical reports
Latest result
-46.2%
Oct 28, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Oct 28, 2026—-$1.06-$1.55-46.2%——
Jul 29, 2026—-$1.23-$1.10+10.6%——
Apr 29, 2026—-$1.01-$1.37-35.6%——
Feb 11, 2026—-$0.89-$1.38-55.1%$1.92M—
Oct 22, 2025—-$0.70-$0.81-15.7%——
Jul 23, 2025—-$0.44-$0.58-31.8%——
Apr 23, 2025—-$0.34-$0.41-20.6%——
Feb 5, 2025—-$0.28-$0.32-14.3%——

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
19
Buy
2
Hold
12-month analyst target
$79.67
+172.64% versus current price
Based on 21 analyst observations. Targets are estimates, not predictions.
Low target
$34.00
+16.36% vs latest price
Average target
$79.67
+172.64% vs latest price
High target
$120.00
+310.68% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 10, 2027

Next known earnings or reporting date.

EPS estimate-$1.38

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score47

Where event reaction would show up first.

AIQ score41/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
21
Average target
$79.67
Target upside
172.64%
Target range
$34.00 - $120.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
1
Negative
0
seekingalpha.com · Oct 31, 2026

Viking Therapeutics: A Strong Injection, A Scaled-Back Pill (NASDAQ:VKTX)

Viking Therapeutics is advancing VK2735, a dual GLP-1/GIP agonist for obesity, with Phase 3 injection results expected in 2027. Read why VKTX stock is a hold.

zacks.com · Oct 23, 2026

Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $24.42, signifying a -5.48% move from its prior day's close.

gurufocus.com · Oct 20, 2026

VKTX Maintained by Canaccord Genuity -- Price Target Lowered to $106

Viking Therapeutics (VKTX) Analyst Rating Update On October 20, 2026, Canaccord Genuity maintained a Buy rating for Viking Therapeutics (VKTX). The price tar

rttnews.com · Sep 24, 2026

Viking Therapeutics Stock Falls 15% After $483 Mln Equity And Convertible Notes Offering

Viking Therapeutics, Inc. (VKTX) is down 15.20 percent, losing $6.33 to $35.32 on Thursday. The move comes after the biotechnology company priced concurrent offerings of 7.

insidermonkey.com · Sep 22, 2026

Viking Therapeutics (VKTX) Rockets 35.7% After Weight Loss Drug Trial — What’s The Selling Point?

Viking Therapeutics Inc.

Open full news and sentiment

VKTX Catalysts FAQ

What are the next catalysts for VKTX stock?

VKTX's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move VKTX stock?

Upcoming events that could move VKTX include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could VKTX's next earnings report affect the stock?

VKTX's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive VKTX stock higher?

VKTX could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt VKTX stock?

VKTX could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.